New directions in thrombolytic therapy.

Abstract

Although current thrombolytic agents have proven their clinical benefit, the failure to rapidly reperfuse some patients and the persistent bleeding risk represent areas for improvement in therapy. In the past two years, the field has been advanced by the regulatory approval of agents with greater ease of administration, continued development of new agents and exploration of the use of more advanced antiplatelet therapies in combination with thrombolytic agents. Finally, a new class of directly acting fibrinolytic agents is available.

• Authors: C F Toombs
• Journal: Current opinion in pharmacology (Curr Opin Pharmacol) Vol. 1 Issue 2 Pg. 164-8 (Apr 2001) ISSN: 1471-4892 [Print] England
• PMID: 11714091 (Publication Type: Journal Article, Review)

Chemical References

• Fibrinolytic Agents
• Platelet Glycoprotein GPIIb-IIIa Complex
• Recombinant Proteins
• Fibrin
• Plasminogen Activators
• Tissue Plasminogen Activator
• Urokinase-Type Plasminogen Activator
• Metalloendopeptidases
• alfimeprase
• auR protein, Staphylococcus aureus
• saruplase
• Tenecteplase

Topics

• Animals
• Arterial Occlusive Diseases (drug therapy)
• Catheterization, Central Venous (adverse effects, methods)
• Contraindications
• Fibrin (metabolism)
• Fibrinolytic Agents (pharmacokinetics, pharmacology, therapeutic use)
• Graft Occlusion, Vascular (prevention & control)
• Humans
• Metalloendopeptidases (pharmacokinetics, pharmacology, therapeutic use)
• Plasminogen Activators (pharmacokinetics, pharmacology, therapeutic use)
• Platelet Glycoprotein GPIIb-IIIa Complex (antagonists & inhibitors)
• Recombinant Proteins (pharmacology, therapeutic use)
• Stroke (drug therapy)
• Tenecteplase
• Thrombolytic Therapy (adverse effects, methods)
• Tissue Plasminogen Activator (pharmacokinetics, pharmacology, therapeutic use)
• Urokinase-Type Plasminogen Activator (pharmacology, therapeutic use)